Solvaldi Too Expensive? Not To Patients—Gilead Sciences, Inc. (GILD) Profit Triples On Strong Hep C Drug Sales
4/23/2014 8:24:41 AM
Gilead Sciences, Inc. announced today its results of operations for the quarter ended March 31, 2014. Total revenues for the first quarter of 2014 increased to $5.00 billion from $2.53 billion for the first quarter of 2013. Gilead Sciences Inc. (GILD), with a current value of $112.08B, started the session at $73.00. A quick look at the market, the company’s traded between $71.85 to $73.26 and has traded between $46.70 and $84.88 over the past year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by